argenx NV ADR
USUSDargenx NV ADR (BR:ARGX) — Biotechnology: Biological Products (No Diagnostic Substances). Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 3. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- argenx.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hauptsitz
- Amsterdam, Netherlands
- CEO
- Karen Massey
- Mitarbeiter
- 1 863
- Gegründet
- 2008
- Börsennotiert seit
- 10.07.2014 (BR:ARGX)
- Ausstehende Aktien
- Streubesitz
- 62.43 Mio.
- Marktkapitalisierung
- 63.2 Mrd. USD
- Insider
- 0.01%
- Institutionelle Anleger
- 48.57%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- Rechtsform
- BBEB
- ISIN
- NL0010832176
- LEI
- 7245009C5FZE6G9ODQ71
- FCF
- 904 Mio. USD
- Schulden
- 47.0 Mio. USD0.1 J. FCF
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
Beschreibung
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Neuigkeiten diese Woche
Pressemitteilungen von der Investoren-Website des Unternehmens, täglich aktualisiert. Links führen zur Website des Unternehmens. Die Schlagzeilen sind in der Originalsprache, wie auf der Firmenwebsite.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| VANGUARD SPECIALIZED FUN… | 1.66% | 1.04 Mio. | 2026-07-31 |
| VANGUARD STAR FUNDS-Vang… | 1.46% | 913 032 | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.97% | 605 295 | 2026-06-30 |
| EuroPacific Growth Fund-… | 0.81% | 506 272 | 2026-06-30 |
| iShares Trust-iShares Co… | 0.73% | 459 544 | 2026-07-31 |
| VANGUARD WORLD FUND-Vang… | 0.73% | 458 852 | 2026-05-31 |
| Fidelity Concord Street… | 0.38% | 240 592 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.35% | 219 191 | 2026-07-31 |
| Franklin Custodian Funds… | 0.32% | 200 000 | 2026-06-30 |
| Fidelity Rutland Square… | 0.31% | 193 374 | 2026-07-31 |
| Prudential World Fd., In… | 0.28% | 176 138 | 2026-07-31 |
| Federated Hermes Equity… | 0.28% | 173 045 | 2026-07-31 |
| Pacer Advisors, Inc. | 0% | 794 | 2026-06-30 |
